2024 hair loss treatments
A recent press release from Elevai Labs noted “encouraging data results” from a study conducted by its subsidiary, Elevai Skincare Inc. We don’t have the full details of the study, but it was mentioned in the press release that it is an ongoing study in which patients with androgenic alopecia were treated with Elevai Exosomes.…
Read More
The US Food and Drug Administration (FDA) has recently approved deuruxolitinib, an oral Janus Kinase (JAK) inhibitor developed by Sun Pharma, for treating severe alopecia areata in adults. What is Deuruxolitinib? Deuruxolitinib, sold under the brand name Leqselvi, is an oral JAK inhibitor that selectively targets JAK1 and JAK2, proteins involved in the immune signaling…
Read More
Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il Messaggero, quote “The most curious thing is that the currently candidate drug,…
Read More
Soterios Pharma, a biopharmaceutical company based in the UK, has announced promising topline results from their Phase 2 study of STS-01, a topical treatment for mild-to-moderate alopecia areata (AA). What is STS-01? STS-01 is a topical treatment for alopecia areata. It is a cytokine-targeting agent that modulates the inflammatory response and T-cell proliferation by disrupting…
Read More
JW Pharmaceutical has presented positive preclinical data on JW0061, a novel Wnt-targeted hair loss treatment, at the U.S. Society of Investigative Dermatology meeting. What are Wnt-Targeted Hair Loss Treatments? Wnt-targeted hair loss treatments aim to modulate the Wnt/ß-catenin signaling pathway, which plays an important role in hair follicle development, hair growth cycle regulation, and hair…
Read More
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read More